Search

Your search keyword '"Andresen, Corina"' showing total 30 results
Start Over Author "Andresen, Corina"
30 results on '"Andresen, Corina"'

2. Interim report of a phase 2 study of sonodynamic therapy (SDT) using SONALA-001 together with MR-guided low-intensity focused ultrasound (MRgFUS) in children with diffuse intrinsic pontine glioma (DIPG).

Author

Kilburn, Lindsay Baker, primary, Packer, Roger J., additional, Fonseca, Adriana, additional, Keating, Robert F, additional, Mueller, Sabine, additional, Narsinh, Kazim, additional, Ho, Winson S, additional, Niazi, Toba, additional, Fenn, Peter, additional, Clanton, Ryan, additional, Henry, Lenora, additional, Potter, Wyatt, additional, Andresen, Corina, additional, Marcus, Stuart, additional, Benaim, Ely, additional, and Syed, Hasan R, additional

Published
2024
Full Text
View/download PDF

3. Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma

Author

Hong, David S, Kurzrock, Razelle, Falchook, Gerald S, Andresen, Corina, Kwak, Jennifer, Ren, Min, Xu, Lucy, George, Goldy C, Kim, Kevin B, Nguyen, Ly M, O’Brien, James P, and Nemunaitis, John

Subjects
Clinical Research, Clinical Trials and Supportive Activities, Cancer, Patient Safety, Rare Diseases, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dacarbazine, Dose-Response Relationship, Drug, Female, Humans, Male, Maximum Tolerated Dose, Melanoma, Middle Aged, Phenylurea Compounds, Quinolines, Temozolomide, Young Adult, lenvatinib, melanoma, pharmacodynamic, phase 1b, advanced solid tumors, Oncology and Carcinogenesis
Abstract

Objective and methodsIn this phase 1b study, patients with stage 4 or unresectable stage 3 melanoma were treated with escalating doses of lenvatinib (once daily) and temozolomide (TMZ) (days 1-5) in 28-day cycles, to determine the maximum tolerated dose (MTD) of the combination. Dose Level (DL)1: lenvatinib 20 mg, TMZ 100 mg/m2; DL2: lenvatinib 24 mg, TMZ 100 mg/m2; DL3: lenvatinib 24 mg, TMZ 150 mg/m2. Adverse events (AEs) were recorded and tumor response assessed per RECIST 1.0.ResultsDose-limiting toxicity occurred in 1 of 32 treated patients (DL1); MTD was not reached. The highest dose administered was lenvatinib 24 mg + TMZ 150 mg/m2. Most common treatment-related AEs included fatigue (56.3%), hypertension (53.1%), and proteinuria (46.9%). Overall objective response rate was 18.8% (6 patients), all partial response; (DL1, n = 1; DL3, n = 5). Stable disease (SD) ≥ 16 weeks was observed in 28.1% of patients (DL1 and DL2, n = 1 each; DL3, n = 7); 12.5% of patients had SD ≥ 23 weeks. Single and repeat-dose pharmacokinetics of lenvatinib were comparable across cycles and with concomitant TMZ administration.ConclusionsLenvatinib 24 mg/day + TMZ 150 mg/m2/day (days 1-5) demonstrated modest clinical activity, an acceptable safety profile, and was administered without worsening of either lenvatinib- or TMZ-related toxicities in this patient group.

Published
2015

4. INNV-14. INTERIM REPORT OF A PHASE 1/2 STUDY OF SONODYNAMIC THERAPY (SDT) USING AMINOLEVULINIC ACID (ALA) AND LOW-INTENSITY FOCUSED ULTRASOUND IN PEDIATRIC PATIENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

Author

Syed, Hasan, primary, Kilburn, Lindsay, additional, Packer, Roger, additional, Keating, Robert, additional, Mueller, Sabine, additional, Patel, Nirali, additional, Fenn, Peter, additional, Clanton, Ryan, additional, Andresen, Corina, additional, Marcus, Stuart, additional, and Benaim, Ely, additional

Published
2023
Full Text
View/download PDF

5. Supplementary Tables S1 and S2 from Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma

Author

Hong, David S., primary, Kurzrock, Razelle, primary, Wheler, Jennifer J., primary, Naing, Aung, primary, Falchook, Gerald S., primary, Fu, Siqing, primary, Kim, Kevin B., primary, Davies, Michael A., primary, Nguyen, Ly M., primary, George, Goldy C., primary, Xu, Lucy, primary, Shumaker, Robert, primary, Ren, Min, primary, Mink, Jennifer, primary, Bedell, Cynthia, primary, Andresen, Corina, primary, Sachdev, Pallavi, primary, O'Brien, James P., primary, and Nemunaitis, John, primary

Published
2023
Full Text
View/download PDF

6. Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial

Author

Pal, Sumanta K, primary, Somford, Diederik M, additional, Grivas, Petros, additional, Sridhar, Srikala S, additional, Gupta, Shilpa, additional, Bellmunt, Joaquim, additional, Sonpavde, Guru, additional, Fleming, Mark T, additional, Lerner, Seth P, additional, Loriot, Yohann, additional, Hoffman-Censits, Jean, additional, Valderrama, Begoña P, additional, Andresen, Corina, additional, Schnabel, Marco J, additional, Cole, Suzanne, additional, and Daneshmand, Siamak, additional

Published
2022
Full Text
View/download PDF

7. Adjuvant infigratinib as targeted therapy for patients with muscle-invasive urothelial carcinoma harboring susceptible FGFR3 genetic alterations: A randomized, double-blind, placebo-controlled, phase 3 trial (PROOF 302).

Author

Cole, Suzanne, primary, Daneshmand, Siamak, additional, Gupta, Shilpa, additional, Diamond, Elan, additional, Master, Viraj A., additional, Roghmann, Florian, additional, De Santis, Maria, additional, Satkunasivam, Raj, additional, Jayram, Gautam, additional, Fornarini, Giuseppe, additional, Freres, Pierre, additional, Mendez-Vidal, Maria Jose, additional, Sridhar, Srikala S., additional, Grivas, Petros, additional, Bellmunt, Joaquim, additional, Ge, Sijian, additional, Andresen, Corina, additional, Pal, Sumanta K., additional, and Lerner, Seth P., additional

Published
2022
Full Text
View/download PDF

8. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment

Author

Cabanillas, Maria E., Schlumberger, Martin, Jarzab, Barbara, Martins, Renato G., Pacini, Furio, Robinson, Bruce, McCaffrey, Judith C., Shah, Manisha H., Bodenner, Donald L., Topliss, Duncan, Andresen, Corina, OʼBrien, James P., Ren, Min, Funahashi, Yasuhiro, Allison, Roger, Elisei, Rossella, Newbold, Kate, Licitra, Lisa F., Sherman, Steven I., and Ball, Douglas W.

Published
2015
Full Text
View/download PDF

9. Targeting alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial.

Author

Pal, Sumanta K, Somford, Diederik M, Grivas, Petros, Sridhar, Srikala S, Gupta, Shilpa, Bellmunt, Joaquim, Sonpavde, Guru, Fleming, Mark T, Lerner, Seth P, Loriot, Yohann, Hoffman-Censits, Jean, Valderrama, Begoña P, Andresen, Corina, Schnabel, Marco J, Cole, Suzanne, and Daneshmand, Siamak

Subjects
BLADDER tumors, ADJUVANT chemotherapy, CLINICAL trials, UREA, HETEROCYCLIC compounds, CELL receptors, ANTINEOPLASTIC agents, TRANSITIONAL cell carcinoma, RESEARCH funding
Abstract

PROOF 302 is an ongoing randomized, double-blind, placebo-controlled, adjuvant phase III trial (NCT04197986) in approximately 218 patients from 120 centers worldwide. Eligibility criteria include post-surgical high-risk muscle-invasive upper tract urothelial cancer (85% of patients) or urothelial bladder cancer (15%), susceptible FGFR3 alterations (activating mutations, gene fusions or rearrangements), ≤120 days following radical surgery and ineligible for/or refusing cisplatin-based (neo)adjuvant chemotherapy. Patients receive either oral infigratinib 125 mg or placebo daily on days 1-21 of a 28-day cycle for up to 52 weeks or until recurrence, unacceptable toxicity or death. Primary end point: centrally determined disease-free survival (DFS); secondary end points: investigator-assessed DFS, metastasis-free survival, overall survival and safety/tolerability; exploratory end points: correlative biomarker analysis, quality-of-life and infigratinib pharmacokinetics. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

10. Phase I comparability of recombinant human albumin and human serum albumin

Author

Bosse, Dietrich, Praus, Michaela, Kiessling, Peter, Nyman, Lars, Andresen, Corina, Waters, Joanne, and Schindel, Fritz

Subjects
Serum albumin -- Testing -- Research, Pharmacokinetics -- Research, Health, Testing, Research
Abstract

Recombinant human albumin (rHA) is a highly purified animal-, virus-, and prion-free product developed as an alternative to human serum albumin (HSA), to which it is structurally equivalent. The present [...]

Published
2005

11. PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations.

Author

Daneshmand, Siamak, primary, Grivas, Petros, additional, Sridhar, Srikala S., additional, Gupta, Shilpa, additional, Bellmunt, Joaquim, additional, Sonpavde, Guru, additional, Fleming, Mark T., additional, Lerner, Seth P., additional, Loriot, Yohann, additional, Wang, Hao, additional, Takkele, Hiywot, additional, Andresen, Corina, additional, Rearden, Jessica, additional, Berman, Craig, additional, and Pal, Sumanta K., additional

Published
2020
Full Text
View/download PDF

12. Infigratinib and treatment response in advanced/unresectable or metastatic urothelial carcinoma in first-line and later-line treatment settings.

Author

Lyou, Yung, primary, Grivas, Petros, additional, Rosenberg, Jonathan E., additional, Hoffman-Censits, Jean H., additional, Quinn, David I., additional, Petrylak, Daniel Peter, additional, Galsky, Matt D., additional, Vaishampayan, Ulka N., additional, De Giorgi, Ugo, additional, Gupta, Sumati, additional, Burris III, Howard A., additional, Rearden, Jessica, additional, Andresen, Corina, additional, Wang, Hao, additional, Daneshmand, Siamak, additional, Bajorin, Dean F., additional, and Pal, Sumanta K., additional

Published
2020
Full Text
View/download PDF

13. Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma.

Author

Yung Lyou, Rosenberg, Jonathan E., Hoffman-Censits, Jean, Quinn, David I., Petrylak, Daniel, Galsky, Matthew, Vaishampayan, Ulka, De Giorgi, Ugo, Gupta, Sumati, Burris, Howard, Rearden, Jessica, Ai Li, Cindy Xu, Andresen, Corina, Moran, Susan, Daneshmand, Siamak, Bajorin, Dean, Pal, Sumanta K., and Grivas, Petros

Subjects
TRANSITIONAL cell carcinoma, FIBROBLAST growth factor receptors, SALVAGE therapy, PROGRESSION-free survival, OVERALL survival, TREATMENT effectiveness
Abstract

The optimal sequencing of systemic treatments for metastatic urothelial cancer (mUC) is unknown. We assessed the efficacy of infigratinib, a fibroblast growth factor receptor (FGFR) 1 to 3 inhibitor, in 67 patients with FGFR3 -altered mUC by line of therapy. Objective response rates were 31% (early-line setting) and 24% (≥2nd-line setting). Infigratinib has notable activity in mUC regardless of line of therapy. Introduction: To describe the efficacy of infigratinib, a potent, selective fibroblast growth factor receptor (FGFR) 1-3 tyrosine kinase inhibitor, across lines of therapy (LOT) in patients with metastatic urothelial cancer (mUC). Patients and Methods: Eligible patients had mUC and prior platinum-based chemotherapy, unless contraindicated, and activating FGFR3 mutation/fusion. Patients received infigratinib 125 mg orally daily (3 weeks on/1 week off) in a single-arm, openlabel study. Primary endpoint: investigator-assessed confirmed objective response rate (ORR). Disease control rate (DCR), progression-free survival (PFS), best overall response (BOR) that included unconfirmed responses, and overall survival (OS) were also assessed. Subgroup analysis of efficacy and safety outcomes by LOT was performed. Results: Sixty-seven patients were enrolled; 13 (19.4%) received infigratinib as early-line therapy for mUC due to ineligibility to receive platinum-based chemotherapy. Overall, ORR was 25.4% (95% CI 15.5-37.5) and DCR was 64.2% (95% CI 51.5-75.5). ORR was 30.8% (95% CI 9.1-61.4) with early-line infigratinib and 24.1% (95% CI 13.5-37.6) for =2 LOT. DCR was 46.2% (95% CI 19.2-74.9) for early-line and 68.5% (95% CI 54.4-80.5) for =2 LOT. PFS and OS appeared similar in both groups. Thirteen of 59 patients with a bladder primary tumor received early-line treatment with an ORR of 30.5% (95% CI 9.1-61.4), and 46 received =2 LOT with an ORR of 20.3% (95% CI 9.4-33.9); BOR was 38.5% (95% CI: 13.9-68.4%) and 42.6% (95% CI: 29.2-56.8%) in the early-line and salvage settings, respectively. Eight patients with upper tract urothelial carcinoma received salvage therapy (ORR, 50.0%; DCR, 100.0%). No significant differences in toxicities between LOT were observed. Conclusion: Infigratinib has notable activity in patients with mUC regardless of LOT. The findings support the evaluation of infigratinib across different settings in mUC. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

14. A phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate-specific antigen (PSA) progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).

Author

Attard, Gerhardt, primary, Borre, Michael, additional, Gurney, Howard, additional, Loriot, Yohann, additional, Andresen, Corina, additional, Kalleda, Ranjith, additional, Pham, Trinh, additional, and Taplin, Mary-Ellen, additional

Published
2017
Full Text
View/download PDF

15. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated t

Author

Cabanillas, Maria E, Schlumberger, Martin, Jarzab, Barbara, Martins, Renato G., Pacini, Furio, Robinson, Bruce, Mccaffrey, Judith C., Shah, Manisha H., Bodenner, Donald L., Topliss, Duncan, Andresen, Corina, O'Brien, James P., Ren, Min, Funahashi, Yasuhiro, Allison, Roger, Elisei, Rossella, Newbold, Kate, Licitra, Lisa F., Sherman, Steven I., and Ball, Douglas W.

Subjects
Cancer Research, Oncology, phase 2, biomarkers, differentiated thyroid cancer, radioiodine refractory, lenvatinib, multikinase inhibitor
Published
2015

16. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma

Author

Hong, David S., primary, Kurzrock, Razelle, additional, Wheler, Jennifer J., additional, Naing, Aung, additional, Falchook, Gerald S., additional, Fu, Siqing, additional, Kim, Kevin B., additional, Davies, Michael A., additional, Nguyen, Ly M., additional, George, Goldy C., additional, Xu, Lucy, additional, Shumaker, Robert, additional, Ren, Min, additional, Mink, Jennifer, additional, Bedell, Cynthia, additional, Andresen, Corina, additional, Sachdev, Pallavi, additional, O'Brien, James P., additional, and Nemunaitis, John, additional

Published
2015
Full Text
View/download PDF

17. A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma.

Author

O'Day, Steven, primary, Gonzalez, Rene, additional, Kim, Kevin, additional, Chmielowski, Bartosz, additional, Kefford, Richard, additional, Long, Georgina, additional, Loquai, Carmen, additional, Cowey, Charles Lance, additional, Hauschild, Axel, additional, Hainsworth, John D., additional, Hersey, Peter, additional, Boyle, Frances, additional, Evans, T. R. Jeffry, additional, Hamid, Omid, additional, Meneses, Nicole, additional, Andresen, Corina, additional, Ren, Min, additional, O'Brien, James P., additional, and Flaherty, Keith, additional

Published
2013
Full Text
View/download PDF

22. A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).

Author

Schlumberger, Martin, primary, Jarzab, Barbara, additional, Cabanillas, Maria E., additional, Robinson, Bruce, additional, Pacini, Furio, additional, Ball, Douglas Wilmot, additional, McCaffrey, Judith C, additional, Newbold, Kate, additional, Allison, Roger, additional, Martins, Renato, additional, Licitra, Lisa F., additional, Shah, Manisha H., additional, Bodenner, Donald, additional, Elisei, Rossella, additional, Burmeister, Lynn A., additional, Funahashi, Yasuhiro, additional, Sellecchia, Rita, additional, Andresen, Corina, additional, O'Brien, James P., additional, and Sherman, Steven I., additional

Published
2012
Full Text
View/download PDF

23. HematideTM, a Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), Assessed for Correction of Anemia in Oncology Patients Receiving Chemotherapy.

Author

Pickering, Lisa M., primary, Cwiertka, Karel, primary, Jassem, Jacek, primary, Petera, Jiri, primary, Pettengell, Ruth, primary, Ramlau, Rodryg, primary, Vorlicek, Jiri, primary, Vyzula, Rostislav, primary, Andresen, Corina, primary, Chang, Stephen, primary, Duliege, Anne-Marie, primary, Leong, Robert, primary, Stead, Richard, primary, and Harper, Peter G., primary

Published
2006
Full Text
View/download PDF

30. Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma

Author

Lyou, Yung, Rosenberg, Jonathan E., Hoffman-Censits, Jean, Quinn, David I., Petrylak, Daniel, Galsky, Matthew, Vaishampayan, Ulka, De Giorgi, Ugo, Gupta, Sumati, Burris, Howard, Rearden, Jessica, Li, Ai, Xu, Cindy, Andresen, Corina, Moran, Susan, Daneshmand, Siamak, Bajorin, Dean, Pal, Sumanta K., and Grivas, Petros

Abstract

To describe the efficacy of infigratinib, a potent, selective fibroblast growth factor receptor (FGFR) 1-3 tyrosine kinase inhibitor, across lines of therapy (LOT) in patients with metastatic urothelial cancer (mUC).

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results